Hsbc Holdings PLC Has $97.77 Million Position in Becton, Dickinson and Company $BDX

Hsbc Holdings PLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 5.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 645,767 shares of the medical instruments supplier’s stock after selling 36,591 shares during the period. Hsbc Holdings PLC owned about 0.23% of Becton, Dickinson and Company worth $97,770,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. SHP Wealth Management bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $29,000. Meeder Asset Management Inc. raised its stake in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares in the last quarter. Finally, Tucker Asset Management LLC bought a new position in Becton, Dickinson and Company in the fourth quarter worth $34,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BDX shares. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Finally, The Goldman Sachs Group dropped their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $187.67.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael Garrison sold 1,100 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,105 shares of company stock worth $1,590,208 in the last quarter. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.0%

Shares of BDX opened at $184.78 on Monday. The company has a market capitalization of $50.91 billion, a P/E ratio of 55.66, a PEG ratio of 13.02 and a beta of 0.21. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The business’s 50 day simple moving average is $170.05 and its 200-day simple moving average is $160.58. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the firm posted $3.68 EPS. The business’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.